EZH2 and Miyoshi myopathy: Several clinical trials are also ongoing involving EZH2 inhibitors in haematological malignancies (NCT02220842, NCT03460977, NCT02395601, NCT02900651), but it appears that the drug(s) are not evaluated in MM patients yet80.